House Bill 984 would create a new North Carolina Cannabis Treatment Research Act and revise existing hemp-extract law to add protections for cannabis used in registered medical research studies. The bill defines cannabis for purposes of the research program, establishes a secure state database for registering research institutions, physicians, caregivers, and patients, and allows qualified participants to possess and use cannabis without criminal penalties when they are part of a registered study and stay within the amount deemed an adequate supply by the research institution.
The bill also authorizes research institutions to approve dispensation of cannabis obtained from another jurisdiction on a case-by-case basis, requires caregivers to register with the Department of Health and Human Services, and makes the identities of registered patients, caregivers, and institutions confidential. It further provides immunity from arrest, prosecution, discipline, or denial of rights or privileges for institutions, physicians, and others participating in the research program or issuing written certifications. The act would take effect July 1, 2025, and apply to offenses committed on or after that date.
HB984 would amend G.S. 90-94.1 and add a new Article 5I to Chapter 90 of the General Statutes, creating a statutory framework for cannabis medical research in North Carolina. It would shift the law from a narrow hemp-extract exemption toward a broader research-based cannabis exemption, while also creating new registration, confidentiality, and enforcement provisions administered by DHHS. The bill would affect research institutions, physicians, caregivers, patients, and law enforcement by defining who may lawfully possess or administer cannabis in the research setting and by limiting criminal penalties for compliant participants.
Based on the available context, the bill appears to have been introduced and referred to committee without recorded debate or votes in the provided materials. The sponsorship by multiple House members suggests active legislative interest in expanding medical cannabis research, but there is no transcript evidence here showing support or opposition from committee members or stakeholders. Overall, the bill’s structure indicates a measured, research-focused approach rather than full legalization, which may be intended to make the proposal more politically acceptable.
The main points of contention likely center on the scope of cannabis access, the creation of a state registry, and the level of immunity granted to participants and institutions. Supporters would likely emphasize medical research, patient access, and scientific study of cannabis as treatment, while opponents may raise concerns about diversion, law enforcement oversight, confidentiality of registrants, and whether the bill effectively expands cannabis use beyond tightly controlled research. Another potential issue is the bill’s interaction with existing controlled-substances law, since it creates exceptions to criminal penalties and allows cannabis acquired from another jurisdiction under institutional approval.